ImmunoPET imaging-based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model.

Fiche publication

Date publication

juin 2023

Journal

European journal of nuclear medicine and molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DENAT Franck , Dr GONCALVES Victor

Tous les auteurs :
Hautiere M, Vivier D, Pineau D, Denis C, Kereselidze D, Herbet A, Costa N, Goncalves V, Selingue E, Larrat B, Hugnot JP, Denat F, Boquet D, Truillet C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37280303

Résumé

The resistance of glioblastoma stem cells (GSCs) to treatment is one of the causes of glioblastoma (GBM) recurrence. Endothelin A receptor (ET) overexpression in GSCs constitutes an attractive biomarker for targeting this cell subpopulation, as illustrated by several clinical trials evaluating the therapeutic efficacy of endothelin receptor antagonists against GBM. In this context, we have designed an immunoPET radioligand combining the chimeric antibody targeting ET, chimeric-Rendomab A63 (xiRA63), with Zr isotope and evaluated the abilities of xiRA63 and its Fab (ThioFab-xiRA63) to detect ET tumors in a mouse model xenografted orthotopically with patient-derived Gli7 GSCs.